|
Market Closed -
Nasdaq
04:00:00 09/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 147.10 USD | +0.17% |
|
-0.27% | +19.85% |
| 10-08 | RBC Lifts Price Target on Gilead Sciences to $126 From $123, Keeps Sector Perform Rating | MT |
| 10-08 | Pharmaceutical Group Sues US Government Over Medicare Drug Pricing Rule | MT |
Company Valuation: Gilead Sciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 91,081 | 107,677 | 100,942 | 115,118 | 152,281 | 182,397 | - | - |
| Change | - | 18.22% | -6.25% | 14.04% | 32.28% | 19.78% | - | - |
| Enterprise Value (EV) 1 | 118,530 | 126,522 | 118,665 | 131,838 | 169,585 | 201,189 | 193,533 | 187,202 |
| Change | - | 6.74% | -6.21% | 11.1% | 28.63% | 18.64% | -3.81% | -3.27% |
| P/E | 14.7x | 23.6x | 18x | 243x | 18.1x | -44.5x | 18.3x | 16.9x |
| PBR | 4.32x | 5.05x | 4.48x | 5.98x | 6.73x | 12.9x | 9.09x | 6.92x |
| PEG | - | -0.9x | 0.8x | -2.7x | 0x | 0x | -0x | 1.99x |
| Capitalization / Revenue | 3.34x | 3.95x | 3.72x | 4x | 5.17x | 5.94x | 5.57x | 5.3x |
| EV / Revenue | 4.34x | 4.64x | 4.38x | 4.59x | 5.76x | 6.55x | 5.91x | 5.43x |
| EV / EBITDA | 8.12x | 8.86x | 9.01x | 11.7x | 10.6x | 25.5x | 10.8x | 10.2x |
| EV / EBIT | 9.45x | 10.4x | 11.3x | 15.5x | 12.9x | 61.6x | 12.2x | 11x |
| EV / FCF | 11x | 15.2x | 16x | 12.8x | 17.9x | -382x | 14.8x | 13.5x |
| FCF Yield | 9.12% | 6.59% | 6.25% | 7.82% | 5.58% | -0.26% | 6.75% | 7.41% |
| Dividend per Share 2 | 2.84 | 2.92 | 3 | 3.08 | 3.16 | 3.293 | 3.352 | 3.015 |
| Rate of return | 3.91% | 3.4% | 3.7% | 3.33% | 2.57% | 2.24% | 2.28% | 2.05% |
| EPS 2 | 4.93 | 3.64 | 4.5 | 0.38 | 6.78 | -3.306 | 8.024 | 8.707 |
| Distribution rate | 57.6% | 80.2% | 66.7% | 811% | 46.6% | -99.6% | 41.8% | 34.6% |
| Net sales 1 | 27,305 | 27,281 | 27,116 | 28,754 | 29,443 | 30,725 | 32,760 | 34,445 |
| EBITDA 1 | 14,598 | 14,283 | 13,177 | 11,287 | 15,953 | 7,885 | 17,879 | 18,401 |
| EBIT 1 | 12,548 | 12,180 | 10,484 | 8,520 | 13,193 | 3,266 | 15,911 | 16,986 |
| Net income 1 | 6,225 | 4,592 | 5,665 | 480 | 8,510 | -4,275 | 10,275 | 10,917 |
| Net Debt 1 | 27,449 | 18,845 | 17,723 | 16,720 | 17,304 | 18,792 | 11,136 | 4,804 |
| Reference price 2 | 72.61 | 85.85 | 81.01 | 92.37 | 122.74 | 147.10 | 147.10 | 147.10 |
| Nbr of stocks (in thousands) | 1,254,384 | 1,254,244 | 1,246,042 | 1,246,266 | 1,240,680 | 1,239,955 | - | - |
| Announcement Date | 1/2/22 | 2/2/23 | 6/2/24 | 11/2/25 | 10/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -44.42x | 6.54x | 25.48x | 2.24% | 182B | |
| 33.76x | 12.26x | 24.76x | 0.58% | 1,060B | |
| 28.75x | 6.35x | 18.21x | 2.07% | 623B | |
| 34.38x | 7.99x | 16.52x | 2.56% | 480B | |
| 103.88x | 5.82x | 24.82x | 2.39% | 352B | |
| 19.43x | 4.75x | 11.8x | 2.78% | 345B | |
| 20.28x | 5.28x | 13.08x | 3.01% | 274B | |
| 20.79x | 4.27x | 12.2x | 2.08% | 249B | |
| 26.09x | 6.8x | 12.11x | 2.44% | 223B | |
| 11.3x | 4.13x | 8.62x | 4.49% | 168B | |
| Average | 25.42x | 6.42x | 16.76x | 2.46% | 395.61B | |
| Weighted average by Cap. | 31.30x | 7.68x | 18.64x | 2.02% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GILD Stock
- Valuation Gilead Sciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
